CF Drug's hidden impact on bones and muscles revealed
NCT ID NCT04206436
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how CFTR modulators, a type of cystic fibrosis treatment, affect bone strength and muscle mass in adults with CF. Researchers will measure changes in bone density and lean body mass over 12 to 24 months. The goal is to understand whether these treatments help or harm bone and muscle health. About 63 adults with confirmed CF are taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE LOSS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University
Indianapolis, Indiana, 46202-5149, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Muscle-Saving supplement may shield seniors from Weight-Loss drug side effect
- Bedrest be gone? gamified therapy aims to keep seniors moving in the hospital
- A smartphone tool may help cystic fibrosis patients survive the lung transplant waitlist
- Can a smartphone app reveal how CF treatments really work at home?
- A common supplement may shield bones in kidney disease — a trial puts it to the test
- Pumping iron to fight cancer's hidden immune toll